Li Jia-Peng, Fu Meng-Meng, Li Xiao-Xue, Xu Ming
Department of Clinical Pharmacy, School of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Br J Pharmacol. 2024 Jul 12. doi: 10.1111/bph.16475.
Diabetes mellitus is a long-term metabolic condition characterized by high blood glucose levels. This disorder is closely associated with a range of complications affecting small and large blood vessels, including conditions like retinopathy, nephropathy and neuropathy, as well as ischaemic heart disease, peripheral vascular disease and cerebrovascular disease. These complications cause organ and tissue damage in an estimated 33% to 50% of individuals with diabetes. The management of these complications in patients with diabetes is confronted with significant clinical challenges. Present treatment modalities for cardiovascular complications secondary to diabetes are limited and exhibit suboptimal efficacy. Cell-based therapies has shown great promise in regenerative medicine and improving cardiovascular function in individuals with diabetic complications, attributed to their potential for multilineage differentiation and regenerative capacity. In this review, we focus on diabetic cardiovascular complications and provide a brief introduction to the application of cell-based therapies, including the use of stem cells and progenitor cells, their mechanisms of action and the prospects and challenges.
糖尿病是一种以血糖水平升高为特征的长期代谢性疾病。这种疾病与一系列影响小血管和大血管的并发症密切相关，包括视网膜病变、肾病和神经病变等病症，以及缺血性心脏病、外周血管疾病和脑血管疾病。这些并发症估计会导致33%至50%的糖尿病患者出现器官和组织损伤。糖尿病患者这些并发症的管理面临重大临床挑战。目前针对糖尿病继发心血管并发症的治疗方式有限，且疗效欠佳。基于细胞的疗法在再生医学以及改善糖尿病并发症患者的心血管功能方面显示出巨大潜力，这归因于它们具有多谱系分化的潜力和再生能力。在这篇综述中，我们聚焦于糖尿病心血管并发症，并简要介绍基于细胞的疗法的应用，包括干细胞和祖细胞的使用、它们的作用机制以及前景和挑战。
